Leukeran (Chlorambucil)

Chlorambucil works by alkylating DNA, creating cross‑links that prevent DNA replication and transcription. This disruption leads to apoptosis of rapidly dividing cancer cells, thereby reducing tumor burden in affected patients.

The dosage of Leukeran is individualized by the prescribing physician based on the specific cancer type, disease stage, patient weight, and renal and hepatic function. Patients should follow the dose and schedule provided by their healthcare professional.

Leukeran is classified as Pregnancy Category D, indicating evidence of fetal risk, and it is contraindicated during pregnancy. It is also not recommended for breastfeeding mothers because chlorambucil can be excreted in breast milk and may harm the infant.

To order Leukeran, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Leukeran (chlorambucil) is an oral alkylating agent, whereas many alternative therapies for similar indications are administered intravenously (e.g., cyclophosphamide). Oral administration offers convenience, but chlorambucil may have a different toxicity profile, especially regarding bone‑marrow suppression and secondary malignancy risk.

Leukeran tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged.

Leukeran is taken orally as a tablet, usually with water. The prescribing physician determines the exact dosing schedule, which may involve daily or intermittent dosing depending on the treatment protocol.

The most serious risks include severe bone‑marrow suppression leading to pancytopenia, life‑threatening infections, secondary cancers such as acute leukemia, hepatic toxicity, and rare but serious pulmonary complications. Patients should be monitored closely for these adverse events.

Leukeran should not be used by pregnant women, nursing mothers, or patients with known hypersensitivity to chlorambucil. Caution is advised in individuals with severe renal or hepatic impairment, and it should be avoided in patients receiving other potent alkylating agents without specialist supervision.